Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to pioneer new products with a mission to dramatically improve the lives of patients with severe autoimmune and inflammatory diseases who continue to suffer with high unmet medical needs. By bringing treatments designed to restore the balance of the immune system, we hope to restore the balance of life for patients in need.
Our lead product candidate, itolizumab, is a first-in-class monoclonal antibody that targets the CD6-ALCAM signaling pathway, which plays a central role in the activation and trafficking of pathogenic effector T cells that drive inflammation in a number of diseases. We believe itolizumab may have broad therapeutic utility and our current pipeline is focused on developing itolizumab as a best-in-class treatment for multiple severe immuno-inflammatory disorders – this includes acute graft-versus-host disease, SLE / lupus nephritis and uncontrolled asthma.
Company Details
- Employees
- 39
- Founded
- -
- Address
- 2223 Avenida De La Playa, San Diego,california,united States
- Phone
- 858 412 5302
- in****@****bio.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- equilliumbio.com
- HQ
- San Diego, California
Equillium, Inc. Questions
Equillium, Inc.'s helpline number is 858 412 5302
Equillium, Inc.'s website is equilliumbio.com
Equillium, Inc.'s LinkedIn profile is https://www.linkedin.com/company/equillium
Equillium, Inc. has
39 employees.
View email and phone details for 39
employees at Equillium, Inc..
Equillium, Inc.'s industry is
Biotechnology Research
Equillium, Inc.'s top competitors are
Blossomhill Therapeutics, Inc.,
Ionis Pharmaceuticals, Inc.,
Fate Therapeutics Inc.,
Synteract,
Travere Therapeutics,
Crinetics Pharmaceuticals,
Acadia Pharmaceuticals Inc.,
Zentalis Pharmaceuticals,
Vivtex,
Avidity Biosciences, Inc..
Equillium, Inc.'s support email address is info@equilliumbio.com
Equillium, Inc.'s categories are Biotechnology Research
Equillium, Inc.'s founding year is 2017
